| Baxter International Inc (BAX) | |||
|---|---|---|---|
| 24.7 0.19 (0.78%) | 10-21 16:00 | ||
| Open: | 24.36 | Pre. Close: | 24.51 |
| High: | 24.825 | Low: | 24.26 |
| Volume: | 5,375,651 | Market Cap: | 12,770(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 30.36 One year: 35.46 |
| Support: | Support1: 23.87 Support2: 22.56 |
| Resistance: | Resistance1: 25.99 Resistance2: 30.36 |
| Pivot: | 24.51 |
| Moving Averages: | MA(5): 25.05  MA(20): 24.27 MA(100): 23.63 MA(250): 20.75 |
| MACD: | MACD(12,26): 0.17 Signal(12,26,9): 0.07 |
| %K %D: | %K(14,3): 54.69 %D(3): 65.11 |
| RSI: | RSI(14): 52.37 |
| 52-Week: | High: 30 Low: 15.73 Change(%): 7.9 |
| Average Vol(K): | 3-Month: 6732 10-Days: 5608 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 24.842 - 24.992 | 24.992 - 25.135 |
| Low: | 23.907 - 24.082 | 24.082 - 24.251 |
| Close: | 24.428 - 24.689 | 24.689 - 24.94 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BAX ] has closed below upper band by 42.0%. Bollinger Bands are 28.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Medical - Instruments & Supplies | |
| Shares Out. (M) | 517.00 |
| Shares Float (M) | 514.41 |
| % Held by Insiders | 0.34 |
| % Held by Institutions | 110.24 |
| Shares Short (K) | 24370 |
| Shares Short Prior Month (K) | 23290 |
| Stock Financials | |
|---|---|
| EPS | -1.920 |
| Book Value (p.s.) | 12.000 |
| Profit Margin | -9.27 |
| Operating Margin | 14.43 |
| Return on Assets (ttm) | 2.8 |
| Return on Equity (ttm) | -14.4 |
| Qtrly Rev. Growth | 5.3 |
| Gross Profit (p.s.) | 7.563 |
| Sales Per Share | 22.186 |
| EBITDA (p.s.) | 3.636 |
| Qtrly Earnings Growth | 36.80 |
| Operating Cash Flow (M) | 1320.00 |
| Levered Free Cash Flow (M) | 1000.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | -12.86 |
| PEG Ratio | 36.68 |
| Price to Book value | 2.06 |
| Price to Sales | 1.11 |
| Price to Cash Flow | 9.67 |
| Stock Dividends | |
|---|---|
| Dividend | 0.010 |
| Dividend Yield | |
| Dividend Growth | |
